These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 6963834)

  • 1. [Clinical characteristics of primary hyperlipoproteinemia type IV. An analysis of 86 patients].
    Kusić M; Gavrilović M; Mihajlović M; Marković N
    Zb Vojnomed Akad; 1981; 23():15-9. PubMed ID: 6963834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Xanthomatosis in patients with hyperlipoproteinemia].
    Kusić M; Stanković K; Gavrilović M
    Zb Vojnomed Akad; 1982; 24():14-8. PubMed ID: 6964904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Platelet half-life in patients with primary hyperlipoproteinemia type IIa, IIb, and IV according to Fredrickson with and without clinical signs of atherosclerosis].
    Jäger E; Sinzinger H; Widhalm K; Kaliman J; Höfer R
    Wien Klin Wochenschr; 1982 Sep; 94(16):421-5. PubMed ID: 7147981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Musculoskeletal symptoms in patients with primary hyperlipoproteinemia. A prelimary study].
    Brekke SE; Kogstad OA
    Tidsskr Nor Laegeforen; 1979 Oct; 99(29):1444-6. PubMed ID: 516016
    [No Abstract]   [Full Text] [Related]  

  • 5. [Diagnosis of primary hyperlipoproteinemia during a preventive examination].
    Raslová K; Mongiellová V; Hucková M
    Cas Lek Cesk; 1993 Mar; 132(5):137-41. PubMed ID: 8472293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Localization of vessel lesions in arteriosclerosis and blood lipid composition].
    Lipovetskiĭ BM; Vinogradova TV
    Ter Arkh; 2002; 74(2):55-7. PubMed ID: 11899828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of hyperlipoproteinemia on blood fibrinolytic activity and thrombocyte aggregation].
    Kostić N; Secen S
    Med Pregl; 2000; 53(3-4):180-3. PubMed ID: 10965685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Increase in the fibrinolytic activity in patients with hyperlipoproteinemias type IV treated with bezafibrate].
    Obispo TM; García Fradé LJ; García Avelló A; César J; Sastre A; Navarro JL
    Rev Clin Esp; 1988 Feb; 182(3):151-4. PubMed ID: 3368592
    [No Abstract]   [Full Text] [Related]  

  • 9. [Biochemical diagnosis of hereditary hyperlipoproteinemias].
    Tvorogova MG; Rozhkova TA; Alidzhanova KhG; Semenova OA; Sobolev AV; Kukharchuk VV; Titov VN
    Ter Arkh; 1998; 70(4):9-15. PubMed ID: 9612894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum phospholipids in patients in a chronic hemodialysis program].
    Ristić V; Tepsić V; Perunicić G; Rasić Z; Bokan L; Pljesa S
    Med Pregl; 1996; 49(7-8):269-71. PubMed ID: 8926942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Eruptions "overnight". Eruptive xanthomas in secondary type IV hyperlipoproteinemia caused by diabetes mellitus].
    Füessl HS
    MMW Fortschr Med; 1999 Aug; 141(31-32):47-8. PubMed ID: 10726123
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
    Bonora V; Calalabuig RJ; Caviola E; Soler J; Pueyo JM; Micaló T; Cano RP
    Clin Ther; 1981; 4(3):192-200. PubMed ID: 7030489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Primary hyperlipoproteinemia in its clinical and laboratory aspects. IV. Blood coagulation and fibrinolysis indicators].
    Borodin M; Jurek D; Gregorczyk J; Pieczul-Mróz J; Cwajda H
    Przegl Lek; 1983; 40(10):727-32. PubMed ID: 6665208
    [No Abstract]   [Full Text] [Related]  

  • 14. [Lipoprotein lipase activity of ischemic heart disease patients with different types of hyperlipoproteinemia on the basis of fat loading].
    Nikul'cheva NG; Soliternova IB; Krivoruchenko IV
    Vopr Med Khim; 1980; 26(6):808-13. PubMed ID: 7456412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xanthine oxidase and triglycerides in serum of patients with hyperlipoproteinemia, type IV.
    Povoa H; Sá LD; Lessa VM
    Biomed Biochim Acta; 1984; 43(10):1201-3. PubMed ID: 6549257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fibrinolytic capacity after exertion in atherogenic hyperlipoproteinemias].
    Zdrenghea D; Mărcuşu C; Cucuianu M; Rentsch S
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1979; 31(5):435-40. PubMed ID: 44567
    [No Abstract]   [Full Text] [Related]  

  • 17. [Changes in serum lipoproteins in patients with ischemic heart disease at an early age].
    Malamov E; Kiriakov A; Tsenov I; Kavrukova Iu; Kusitasev G
    Vutr Boles; 1982; 21(2):91-8. PubMed ID: 7101895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemorrheologic abnormalities in defined primary dyslipoproteinemias with both high and low atherosclerotic risks.
    Otto C; Ritter MM; Richter WO; Minkenberg R; Schwandt P
    Metabolism; 2001 Feb; 50(2):166-70. PubMed ID: 11229424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Lipid status in patients on a chronic hemodialysis program].
    Tepsić V; Ristić V; Perunicić G; Rasić Z; Pljesa S; Bokan L; Ranković N
    Med Pregl; 1997; 50(1-2):45-7. PubMed ID: 9132551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Behaviour of uricemia in hyperlipoproteinemic subjects.
    Zdrenghea D; Marta D; Constantinescu M; Cucuianu M
    Med Interne; 1980; 18(4):385-90. PubMed ID: 7455583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.